FRED HUTCHINSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Employees: -

Market Cap: -

Website: https://www.fredhutch.org

Clinical Trials

Early Discharge and Outpatient Care After Chemotherapy in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia

Not Applicable

Completed

Conditions: Leukemia
Myelodysplastic Syndromes

First Posted Date: 2009-02-16

Last Posted Date: 2011-05-19

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 96

Registration Number: NCT00844441

Locations: 🇨🇭
Clinical Cancer Research Center at University Hospital Basel, Basel, Switzerland
🇺🇸
Oregon Health and Science University, Portland, Oregon, United States
🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Clofarabine and Cytarabine in Treating Older Patients With AML or High-Risk MDS

Phase 1

Completed

Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Myeloid Leukemia With Del(5q)
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
Myelodysplastic Syndrome With Isolated Del(5q)
Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
Previously Treated Myelodysplastic Syndromes
Recurrent Adult Acute Myeloid Leukemia

Interventions: Drug: clofarabine
Drug: cytarabine

First Posted Date: 2009-02-10

Last Posted Date: 2017-07-11

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 35

Registration Number: NCT00839982

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Bortezomib and Vorinostat in Treating Patients With Multiple Myeloma Who Have Undergone Autologous Stem Cell Transplant

Phase 2

Completed

Conditions: DS Stage I Plasma Cell Myeloma
DS Stage III Plasma Cell Myeloma
DS Stage II Plasma Cell Myeloma

Interventions: Drug: Bortezomib
Drug: Vorinostat

First Posted Date: 2009-02-10

Last Posted Date: 2017-05-09

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 31

Registration Number: NCT00839956

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Lenalidomide With or Without Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Have Undergone Autologous or Syngeneic Stem Cell Transplant

Phase 2

Withdrawn

Conditions: Leukemia
Lymphoma

Interventions: Drug: lenalidomide
Biological: rituximab

First Posted Date: 2009-02-02

Last Posted Date: 2015-03-06

Lead Sponsor: Fred Hutchinson Cancer Center

Registration Number: NCT00833534

Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematological Cancer Who Are Undergoing Umbilical Cord Blood Transplant

Phase 2

Completed

Conditions: Acute Biphenotypic Leukemia
Acute Lymphoblastic Leukemia in Remission
Acute Myeloid Leukemia in Remission
Blasts Under 5 Percent of Bone Marrow Nucleated Cells
Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Myelodysplastic Syndrome (MDS)

Interventions: Drug: Cyclosporine
Drug: Fludarabine Phosphate
Other: Laboratory Biomarker Analysis
Drug: Mycophenolate Mofetil
Radiation: Total-Body Irradiation
Drug: Treosulfan
Procedure: Umbilical Cord Blood Transplantation

First Posted Date: 2008-11-24

Last Posted Date: 2023-02-17

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 130

Registration Number: NCT00796068

Locations: 🇺🇸
Oregon Health and Science University, Portland, Oregon, United States
🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
🇺🇸
University of Colorado Hospital, Aurora, Colorado, United States

Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant

Phase 2

Completed

Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Atypical Chronic Myeloid Leukemia, BCR-ABL Negative
Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable
Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma
Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma
Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma
Recurrent Grade 1 Follicular Lymphoma
Recurrent Mantle Cell Lymphoma
Recurrent Mycosis Fungoides/Sezary Syndrome

Interventions: Drug: ondansetron
Other: survey administration
Procedure: management of therapy complications

First Posted Date: 2008-11-21

Last Posted Date: 2017-05-23

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 49

Registration Number: NCT00795769

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Autologous or Syngeneic Stem Cell Transplant Followed by Donor Stem Cell Transplant and Bortezomib in Treating Patients With Newly Diagnosed High-Risk, Relapsed, or Refractory Multiple Myeloma

Phase 2

Completed

Conditions: Refractory Plasma Cell Myeloma

Interventions: Procedure: Autologous Hematopoietic Stem Cell Transplantation
Drug: Bortezomib
Drug: Cyclosporine
Drug: Fludarabine Phosphate
Other: Laboratory Biomarker Analysis
Drug: Melphalan
Drug: Mycophenolate Mofetil
Procedure: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation
Procedure: Peripheral Blood Stem Cell Transplantation
Procedure: Syngeneic Bone Marrow Transplantation
Radiation: Total-Body Irradiation

First Posted Date: 2008-11-19

Last Posted Date: 2020-01-22

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 32

Registration Number: NCT00793572

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer

Phase 1

Completed

Conditions: Acute Lymphoblastic Leukemia
Diffuse Large B-Cell Lymphoma
Acute Myeloid Leukemia
Refractory Chronic Lymphocytic Leukemia
Aggressive Non-Hodgkin Lymphoma
Refractory Plasma Cell Myeloma
Recurrent Chronic Lymphocytic Leukemia
Refractory Hodgkin Lymphoma
Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Recurrent Indolent Adult Non-Hodgkin Lymphoma

Interventions: Procedure: Allogeneic Bone Marrow Transplantation
Drug: Cyclophosphamide
Drug: Fludarabine Phosphate
Other: Laboratory Biomarker Analysis
Drug: Mycophenolate Mofetil
Biological: Natural Killer Cell Therapy
Drug: Tacrolimus
Radiation: Total-Body Irradiation

First Posted Date: 2008-11-13

Last Posted Date: 2020-01-31

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 41

Registration Number: NCT00789776

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
🇺🇸
Children's Hospital of Wisconsin, Milwaukee, Wisconsin, United States
🇺🇸
Froedtert and the Medical College of Wisconsin, Milwaukee, Wisconsin, United States

Blood Samples to Evaluate Biomarkers of Donor Chimerism

Completed

Conditions: Leukemia
Hodgkins Disease
Myelodysplastic Syndrome
Non-hodgkins Lymphoma

First Posted Date: 2008-10-02

Last Posted Date: 2012-02-15

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 80

Registration Number: NCT00764829

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer

Phase 2

Completed

Conditions: Recurrent Plasma Cell Myeloma
Refractory Chronic Myelogenous Leukemia
Refractory Follicular Lymphoma
Recurrent Chronic Lymphocytic Leukemia
Recurrent Mantle Cell Lymphoma
Recurrent Marginal Zone Lymphoma
Recurrent T-Cell Non-Hodgkin Lymphoma
Recurrent Lymphoplasmacytic Lymphoma
Myelodysplastic Syndrome
Myeloproliferative Neoplasm

Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Drug: Cyclophosphamide
Drug: Cyclosporine
Drug: Fludarabine Phosphate
Other: Laboratory Biomarker Analysis
Drug: Mycophenolate Mofetil
Radiation: Total-Body Irradiation
Procedure: Umbilical Cord Blood Transplantation

First Posted Date: 2008-07-28

Last Posted Date: 2019-12-27

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 73

Registration Number: NCT00723099

Locations: 🇺🇸
University of Colorado Hospital, Aurora, Colorado, United States
🇺🇸
Froedtert and the Medical College of Wisconsin, Milwaukee, Wisconsin, United States
🇺🇸
Colorado Blood Cancer Institute, Denver, Colorado, United States

and more 3 locations

Home Terms & Conditions Privacy Policy